A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease.

Trial Profile

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2018

At a glance

  • Drugs PF 6669571 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Feb 2018 Primary endpoint (Maximum percent change from baseline in Movement Disorder Society-sponsor revision of the Unified Parkinsons Disease Rating Scale (MDS UPDRS) Part III at Day 7.) has not been met as per the the results published in the Clinical Drug Investigation.
    • 24 Feb 2018 Results published in the Clinical Drug Investigation
    • 08 Jul 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top